Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension

American Journal of Kidney Diseases

Volumn 50, Issue 2, 2007, Pages 203-218

  Izzedine, Hassane ^a   Rixe, Olivier ^a   Billemont, Bertrand ^a   Baumelou, Alain ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

anti epidermal growth factor receptor; Anti vascular endothelial growth factor receptor; hypertension; proteinuria

Indexed keywords

AMPHOTERICIN B; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AXITINIB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CANERTINIB; CETUXIMAB; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYBRID PROTEIN; IMATINIB; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; LAPATINIB; PAMIDRONIC ACID; PERTUZUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN TRAP; VATALANIB;

ACNE; ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASTHENIA; BREAST CANCER; CHILL; CHRONIC MYELOID LEUKEMIA; CRYOGLOBULINEMIA; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; EOSINOPHILIA; EPITHELIUM CELL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; INJECTION SITE REACTION; KIDNEY CARCINOMA; KIDNEY COLLECTING TUBULE; KIDNEY DISTAL TUBULE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; PODOCYTE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMACH PARIETAL CELL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANGIOGENESIS INHIBITORS; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES;

EID: 34447635695     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.04.025     Document Type: Review

References (88)

1. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36 (1995) 127-137
2. Lin N.U., and Winer E.P. New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Res 6 (2004) 204-210
3. Emens L.A., and Davidson N.E. Trastuzumab in breast cancer. Oncology (Huntingt) 18 (2004) 1117-1128
4. Roy-Chaudhury P., Jones M.C., MacLeod A.M., Haites N.E., Simpson J.G., and Power D.A. An immunohistological study of epidermal growth factor receptor and neu receptor and neu receptor expression in proliferative glomerulonephritis. Pathology 25 (1993) 327-332
5. Sargent E.R., Gomella L.G., Belldegrun A., Linehan W.M., and Kasid A. Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol 142 (1989) 1364-1368
6. Nakopoulou L., Stefanaki K., Boletis J., et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol Dial Transplant 9 (1994) 764-769
7. Yoshioka K., Takemura T., Murakami K., et al. Identification and localization of epidermal growth factor and its receptor in the human glomerulus. Lab Invest 63 (1990) 189-196
8. Folkman J. Tumor angiogenesis. Adv Cancer Res 19 (1974) 331-358
9. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
10. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., and Leung D.W. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5 (1991) 1806-1814
11. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266 (1991) 11947-11954
12. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
13. Kamba T., Tam B.Y., Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290 (2006) H560-H576
14. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111 (2003) 707-716
15. Mattot V., Moons L., Lupu F., et al. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 13 (2002) 1548-1560
16. Thomas S., Vanuystel J., Gruden G., et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 11 (2000) 1236-1243
17. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 (2003) 12605-12608
18. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
19. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
20. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
21. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18 (2000) 904-914
22. Harari P.M. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11 (2004) 689-708
23. Vidal: Herceptin (ed 82). 2006, pp 962-964. Available at: www.vidal.fr. Accessed: January 15, 2007
24. Jensen B.V. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33 suppl 15 (2006) S15-S21
25. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
26. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
27. Kilic T., Alberta J.A., Zdunek P.R., et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60 (2000) 5143-5150
28. Sjoblom T., Shimizu A., O'Brien K.P., et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61 (2001) 5778-5783
29. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., and Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 359 (2002) 1577-1578
30. Cools J., de Angelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
31. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 (2003) 3093-3096
32. Kitiyakara C., and Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 17 (2002) 685-687
33. Pou M., Saval N., Vera M., et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 44 (2003) 1239-1241
34. Al Aly Z., Philoctete Ashley J.M., Gellens M.E., and Gonzalez E.A. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence?. Am J Kidney Dis 45 (2005) 762-768
35. Foringer J.R., Verani R.R., Tjia V.M., Finkel K.W., Samuels J.A., and Guntupalli J.S. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 39 (2005) 2136-2138
36. Ranson M., and Wardell S. Gefitinib, a novel, orally administered agent for the treatment of cancer. J Clin Pharm Ther 29 (2004) 95-103
37. Roskoski Jr. R. The ErbB/HER receptor proteintyrosine kinases and cancer. Biochem Biophys Res Commun 319 (2004) 1-11
38. Baselga J., and Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 60 suppl 1 (2000) S33-S40
39. Inomata S., Takahashi H., Nagata M., et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 15 (2004) 461-467
40. Kumasaka R., Nakamura N., Shirato K., et al. Side effects of the therapy: Case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 22 (2004) 2504-2505
41. Wan H.L., and Yao N.S. Acute renal failure associated with gefitinib therapy. Lung 184 (2006) 249-250
42. Moyer J.D., Barbacci E.G., Iwata K.K., et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57 (1997) 4838-4848
43. Iwata K, Provoncha K, Gibson N: Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) [abstract 79]. Presented at the Annual Meeting of the American Society of Clinical Oncology, Orlando, 2002
44. Grunwald V., and Hidalgo M. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 30 (2003) 23-31
45. Herbst R.S., Johnson D.H., Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 2544-2555
46. Zhu X., Wu S., Dahut W.L., and Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49 (2007) 186-193
47. Johnson D.H., Fehrenbacher L., and Novotny W.F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
48. Miller K.D., Chap L.I., and Holmes F.A. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
49. George B.A., Zhou X.J., and Toto R. Nephrotic syndrome after bevacizumab: Case report and literature review. Am J Kidney Dis 49 (2007) 23-29
50. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
51. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
52. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
53. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24 (2006) 1363-1369
54. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005 Annual Meeting Proceedings Part I 23(16S), 2005 (June 1 Suppl) (abstr 4510)
55. Rugo H.S., Herbst R.S., Liu G., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23 (2005) 5474-5483
56. Rini B., Rixe O., Bukowski R., et al. AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 23 suppl 1 (2005) S380A abstr 4509
57. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
58. Hecht J.R., Trarbach T., Jaegger E., et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol 23 suppl 1 (2005) S1090A abstr 3
59. Drevs J, Medinger M, Mross K, et al: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005 Annual Meeting Proceedings Part I 23(16S), 2005 (June 1 Suppl) (abstr 3002)
60. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 (2005) 4162-4171
61. Nguyen Q.D., Shah S.M., Hafiz G., et al., CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113 (2006) 1522-1522
62. Izzedine H., Rixe O., Brocheriou I., and Deray G. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 22 (2007) 1481-1482
63. Gilbert R.E., Kelly D.J., McKay T., et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59 (2001) 1324-1332
64. Howie J.B., and Helyer B.J. The immunology and pathology of NZB mice. Adv Immunol 9 (1968) 215-266
65. Foster M.H. Relevance of systemic lupus erythematosus nephritis animal models to human disease. Semin Nephrol 19 (1999) 12-24
66. Lassila M., Jandeleit-Dahm K., Seah K.K., et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 16 (2005) 363-373
67. Schellings M.W., Baumann M., van Leeuwen R.E., et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2) rats. Hypertension 47 (2006) 467-474
68. Francois H., Placier S., Flamant M., et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 18 (2004) 926-928
69. Sane D.C., Anton L., and Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 7 (2004) 193-201
70. McCance K.L., and Huether S.E. Pathophysiology: The Biologic Basis for Disease in Adults and Children. (ed 4) (2002), Mosby, St. Louis, MO
71. Henry T.D., Annex B.H., McKendall G.R., et al. VIVA Investigators: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107 (2003) 1359-1365
72. Tang J.R., Markham N.E., Lin Y.J., et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287 (2004) L344-L351
73. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
74. Wickman G., Hallin M., Salansky K.A., et al. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc Am Assoc Cancer Res 44 (2003) 865A (abstr 3780)
75. Feliers D., Chen X., Akis N., Choudhury G.G., Madaio M., and Kasinath B.S. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int 68 (2005) 1648-1659
76. Safar M.E., Levy B.I., and Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107 (2003) 2864-2869
77. Stefanadis C.I., Karrayannacos P.E., Boudoulas H.K., et al. Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. Cardiovasc Res 27 (1993) 951-956
78. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
79. Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 17 (1991) 144-148
80. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
81. Laurinavicius A., Hurwitz S., and Rennke H.G. Collapsing glomerulopathy in HIV and non-HIV patients: A clinicopathological and follow-up study. Kidney Int 56 (1999) 2203-2213
82. Mares JE, Worah S, Mathew SV: Increased rates of hypertension (HTN) among patients with advanced carcinoma treated by bevacizumab. 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), 2005 (abstr 4087)
83. Hara A., Wada T., Furuichi K., et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int 69 (2006) 1986-1995
84. Kelly D.J., Aaltonen P., Cox A.J., et al. Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: Differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 17 (2002) 1327-1332
85. Kitayama H., Maeshima Y., Takazawa Y., et al. Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. Am J Hypertens 19 (2006) 718-727
86. Sato Y., and Sonoda H. The vasohibin family. A negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol 27 (2007) 37-41
87. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
88. Kabbinavar F.F., Hambleton J., Mass R.D., Hurwitz H.I., Bergsland E., and Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712